trastuzumab biosimilar / Noritsu Koki - LARVOL DELTA

Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer. (PubMed, Appl Biochem Biotechnol) - "The patients then received standard NACT therapy: adriamycin and cyclophosphamide and paclitaxel (AC-T) or AC-TH (AC-T+ Trastuzumab) regimen. The ROC curves to discriminate good neoadjuvant chemotherapy efficiency (Miller-Payne 4-5) and poor efficiency (Miller-Payne 1-3) were created, and AUC value was 0.77. Our results suggested that ctDNA mutation of XRCC1 44055726 (TG>-) might be a positive biomarker for NACT therapy in LABC, while mTOR 11249132(G>C) mutation was potentially associated with NACT resistance."

Circulating tumor DNA • Journal • Breast Cancer • Oncology • Solid Tumor • ABCB1 • BRCA2 • MTHFR • PIK3CA • TP53 • XPC • XRCC1